Etropal AD Valuation

Q: What is the Fair Price of ETR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ETR (BGN4.2) is trading below our estimate of [[fair value]] (BGN30.36)

Is ETR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ETR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ETR (BGN4.2) is trading below our estimate of fair value (BGN30.36)

Significantly Below Fair Value: ETR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ETR?

Key metric: As ETR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ETR. This is calculated by dividing ETR's market cap by their current revenue.
What is ETR's PS Ratio?
PS Ratio	1.5x
Sales	лв13.68m
Market Cap	лв21.00m

ETR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	23.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ETR's PS Ratio compare to its peers?

The above table shows the PS ratio for ETR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.9x
CNSL Cambridge Nutritional Sciences	0.9x	n/a	UK£7.9m
MHHL Mohini Health & Hygiene	0.5x	n/a	₹875.3m
RUA RUA Life Sciences	3.3x	32.2%	UK£7.1m
8622 Huakang Biomedical Holdings	3x	n/a	HK$80.1m
ETR Etropal AD	1.5x	n/a	лв21.0m

Price-To-Sales vs Peers: ETR is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does ETR's PS Ratio compare vs other companies in the European Medical Equipment Industry?

33 Companies	Price / Sales	Estimated Growth	Market Cap

33 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ETR is good value based on its Price-To-Sales Ratio (1.5x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is ETR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ETR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ETR's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Eckert & Ziegler

€831.3m

Manufactures and sells isotope technology components worldwide.

EUZ

€39.45

0.9%

1.2%

Siemens Healthineers

€54.9b

Through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide.

SHL

€48.44

n/a